Table 1 Reasons for the commencement of anti-TNF therapy in patients with different subtypes of JIA
DrugIndicationOligoExt-OP RF−P RF+sJIAERAPsAAll
EtanerceptArthritis119574108099
(n  =  105)Arthritis plus uveitis00500005
Systemic00001001
InfliximabArthritis219345212377
(n  =  104)Uveitis1314000018
Arthritis plus uveitis03400119
  • All patients had increased disease activity: high or moderate. High activity defined as three or more of the following: patients with five or more active joints or erosive arthritis; C-reactive protein ⩾40 mg/l; erythrocyte sedimentation rate ⩾30 mm/h; number of disease-modifying antirheumatic drugs two or more; prednisolone ⩾0.3 mg/kg; sight-threatening uveitis with macular oedema and/or activity of uveitis grade 3+ or greater. Moderate activity: increased disease activity, but less than in those with high activity. ERA, enthesitis-related arthritis; Ext-O, extended oligoarthritis; JIA, juvenile idiopathic arthritis; Oligo, oligoarthritis; P RF−, seronegative polyarthritis, P RF+, seropositive polyarthritis; PsA, psoriatic arthritis; sJIA, systemic juvenile idiopathic arthritis; TNF, tumour necrosis factor.